Rankings
▼
Calendar
FHTX FY 2022 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
FHTX
Foghorn Therapeutics Inc.
$330M
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$19M
+1357.8% YoY
Gross Profit
$19M
100.0% margin
Operating Income
-$117M
-609.2% margin
Net Income
-$109M
-566.3% margin
EPS (Diluted)
$-2.62
Cash Flow
Operating Cash Flow
$194M
Free Cash Flow
$192M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$405M
Total Liabilities
$405M
Stockholders' Equity
$112,000
Cash & Equivalents
$52M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$19M
$1M
+1357.8%
Gross Profit
$19M
$1M
+1357.8%
Operating Income
-$117M
-$101M
-16.3%
Net Income
-$109M
-$101M
-7.5%
← Q4 2021
All Quarters
Q1 2022 →